Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 13 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab in addition to chemotherapy for small cell lung cancer – first line Atezolizumab (Tecentriq; MPDL3280A) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2018 View  |  Download
Durvalumab for limited stage small-cell lung cancer after
1 therapy
Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2022 View  |  Download
Durvalumab with or without tremelimumab in addition to platinum based chemotherapy for extensive-stage disease small-cell lung cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2019 View  |  Download
Durvalumab with tremelimumab for limited stage small-cell lung cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2022 View  |  Download
Lurbinectedin in addition to doxorubicin for small-cell lung cancer after prior platinum-containing therapy Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Lurbinectedin (PM01183; Zepzelca) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2020 View  |  Download
Lurbinectedin with atezolizumab maintenance therapy for extensive-stage small-cell lung cancer Atezolizumab (Tecentriq; MPDL3280A) , Lurbinectedin (PM01183; Zepzelca) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pembrolizumab in addition to standard of care chemotherapy for extensive stage small cell lung cancer – first line Pembrolizumab (Keytruda; MK-3475) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2018 View  |  Download
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer Chemoradiotherapy , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Pembrolizumab-vibostolimab with etoposide and platinum chemotherapy for previously untreated extensive-stage small cell lung cancer Etoposide , Pembrolizumab-vibostolimab (MK-7684; MK7684A; Vibostolimab) , Platinum-based chemotherapy Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Rovalpituzumab tesirine for the treatment of relapsed or refractory small cell lung cancer Rovalpituzumab tesirine (SC16LD6.5; Rova-T) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2017 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications